Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SEATTLE, March 14, 2017 -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that preclinical data for new bispecific antibody candidates targeting CD123 and CD3 will be presented in a poster session at the 2017 Annual Meeting of the American Association for Cancer Research (AACR) to be held in Washington D.C., April 1-5, 2017.
Based on Aptevo’s proprietary ADAPTIR™ protein therapeutic platform, the Company’s latest bispecific candidates targeting CD123 were designed to redirect T-cell cytotoxicity to CD123-expressing tumors cells, a cell surface receptor highly expressed in several hematological malignancies. Results being presented at AACR will examine the in vitro and in vivo activity of optimized lead candidates, APVO436 and APVO437, in preclinical models of acute myeloid leukemia (AML).
| Title: | Bispecific anti-CD123 x anti-CD3 ADAPTIR Molecules for Redirected T-cell Cytotoxicity in Hematological Malignancies |
| Date/Time: | April 2, 2017 – 1:00 – 5:00 pm ET |
| Session Title: | T-Cell Immunity to Cancer – New Progress (Immunology) |
| Abstract ID: | 597/1 |
Abstracts for the AACR annual meeting are available and can be viewed online at www.aacr.org. Aptevo’s poster presentation will be available on the Investor Relations section of the Company’s website at www.aptevotherapeutics.com following the poster session.
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Our core technology is the ADAPTIR™ (modular protein technology) platform. Aptevo has four commercial products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immuno-oncology.
Source: Aptevo Therapeutics Stacey Jurchison Senior Director, Investor Relations and Corporate Communications 206-859-6628 [email protected]
